Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
SHANGHAI, Nov 30, 2024 – (ACN Newswire via SeaPRwire.com) – Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical … Read More